Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma.

Bhalla R, Kunju LP, Tomlins SA, Christopherson K, Cortez C, Carskadon S, Siddiqui J, Park K, Mosquera JM, Pestano GA, Rubin MA, Chinnaiyan AM, Palanisamy N.

Mod Pathol. 2013 Jun;26(6):835-48. doi: 10.1038/modpathol.2012.234. Epub 2013 Jan 25.

2.
3.

Prostate cancer SubtyPINg biomarKers and outcome: is clarity emERGing?

Smith SC, Tomlins SA.

Clin Cancer Res. 2014 Sep 15;20(18):4733-6. doi: 10.1158/1078-0432.CCR-14-0818. Epub 2014 Jun 18. Review.

4.

Current State of ERG as Biomarker in Prostatic Adenocarcinoma.

Acs B, Szarvas T, Szekely N, Nyirady P, Szasz AM.

Curr Cancer Drug Targets. 2015;15(8):643-51. Review.

PMID:
26452381
5.

The oncogene ERG: a key factor in prostate cancer.

Adamo P, Ladomery MR.

Oncogene. 2016 Jan 28;35(4):403-14. doi: 10.1038/onc.2015.109. Epub 2015 Apr 27. Review.

PMID:
25915839
6.

New and Emerging Diagnostic and Prognostic Immunohistochemical Biomarkers in Prostate Pathology.

Giannico GA, Arnold SA, Gellert LL, Hameed O.

Adv Anat Pathol. 2017 Jan;24(1):35-44. Review.

PMID:
27941540
7.

Biomarkers in prostate cancer: new era and prospective.

Mohammed AA.

Med Oncol. 2014 Aug;31(8):140. doi: 10.1007/s12032-014-0140-3. Epub 2014 Jul 22. Review.

PMID:
25048724
8.

Clinical potential of the ERG oncoprotein in prostate cancer.

Rosen P, Sesterhenn IA, Brassell SA, McLeod DG, Srivastava S, Dobi A.

Nat Rev Urol. 2012 Feb 14;9(3):131-7. doi: 10.1038/nrurol.2012.10. Review.

PMID:
22331093
9.

Genomic Rearrangements of PTEN in Prostate Cancer.

Phin S, Moore MW, Cotter PD.

Front Oncol. 2013 Sep 17;3:240. doi: 10.3389/fonc.2013.00240. Review.

10.

Methodological aspects of the molecular and histological study of prostate cancer: focus on PTEN.

Ugalde-Olano A, Egia A, Fernández-Ruiz S, Loizaga-Iriarte A, Zuñiga-García P, Garcia S, Royo F, Lacasa-Viscasillas I, Castro E, Cortazar AR, Zabala-Letona A, Martín-Martín N, Arruabarrena-Aristorena A, Torrano-Moya V, Valcárcel-Jiménez L, Sánchez-Mosquera P, Caro-Maldonado A, González-Tampan J, Cachi-Fuentes G, Bilbao E, Montero R, Fernández S, Arrieta E, Zorroza K, Castillo-Martín M, Serra V, Salazar E, Macías-Cámara N, Tabernero J, Baselga J, Cordón-Cardo C, Aransay AM, Villar AD, Iovanna JL, Falcón-Pérez JM, Unda M, Bilbao R, Carracedo A.

Methods. 2015 May;77-78:25-30. doi: 10.1016/j.ymeth.2015.02.005. Epub 2015 Feb 16. Review.

11.

Advancing precision medicine for prostate cancer through genomics.

Roychowdhury S, Chinnaiyan AM.

J Clin Oncol. 2013 May 20;31(15):1866-73. doi: 10.1200/JCO.2012.45.3662. Epub 2013 Apr 15. Review.

12.

Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer.

Ross AE, D'Amico AV, Freedland SJ.

Prostate Cancer Prostatic Dis. 2016 Mar;19(1):1-6. doi: 10.1038/pcan.2015.31. Epub 2015 Jun 30. Review.

PMID:
26123120

Supplemental Content

Support Center